OncoImmunity will start collaborating with a US-based neoantigen specific T-cell therapy company

OncoImmunity announced today the signing of a collaboration agreement with a T cell therapy company based in the US . The companies will cooperate to access the predictive capabilities of OncoImmunity`s artificial intelligence platform called the Immuneoprofiler™ to identify immunogenic neoantigens for the US partner’s T-cell platform.

The collaboration agreement marks the increasing potential of the Immuneoprofiler™ platform to identify optimal neoantigen targets for personalized cell therapy, in addition to the personalized cancer vaccine market.